Locksley Resources (ASX: LKY) hits 99.5% purity antimony trioxide milestone, opening U.S. defense supply chain pathway
How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure
Read More 6 minute read Pharma Industry News Can fewer infusions improve adherence in Fabry disease enzyme replacement therapy? EU approves monthly Elfabrio dosing for Fabry disease. Discover how reduced infusion frequency could reshape enzyme therapy and treatment burden. bySoujanya RaviMarch 11, 2026